News & Announcements

Lucy Cavendish College launches innovative and unique Life Sciences Community

24 September 2021

The supportive and inclusive collaboration will provide new opportunities for STEMM students and improve employment prospects.

Read More

CC Bio aims to improve health of millions of women and cystic fibrosis patients with microbiome editing technology

24 September 2021

The lives of millions of women around the world could be improved by extraordinary microbiome editing technology pioneered by synthetic biology start-up CC Bio.

Read More

US, China and Japan investors back $37m PetMedix Series B

08 September 2021

Heavyweight Chinese, Japanese and US backing has allowed Cambridge animal healthtech company PetMedix™ to complete an oversubscribed $37 million Series B round to advance its innovative pipeline through clinical development. And the Babraham-based company is looking for more.

Read More

Huntington’s disease progression stopped in cell study by University of Cambridge and UCL researchers

08 September 2021

Exciting progress has been made in the lab in the fight against Huntington’s disease. Scientists at the University of Cambridge and UCL have identified a mechanism that stops its progression in cells.

Read More

All (name) change at the Babraham Research Campus

06 September 2021

Babraham Bioscience Technologies Ltd, which manages and develops the Babraham Research Campus on behalf of its shareholders - BBSRC and the Babraham Institute – is now known as Babraham Research Campus Ltd.

Read More

Springer Nature and Babraham Research Campus partnership looking to bring business journal subscriptions to you at discounted rates

03 September 2021

Babraham Research Campus has partnered up with Springer Nature to offer you the chance to qualify to subscribe to Nature, the leading multidisciplinary journal, at a reduced introductory rate.

Read More

Bacteria blitzer CC Bio wins £890k to fast-track personalised cures

27 August 2021

Award-winning synthetic biology start-up CC Bio has raised £890,000 seed funding from Cambridge-based CMS Ventures to accelerate development of its innovative approach to infection treatment and prevention.

Read More

Cambridge Judge Business School are launching a new programme focusing on sustainability

26 August 2021

Would you like to be a part of the first ever Venture Creation: Sustainability cohort. Participation in the programme will help delegates develop their capacity for future innovation in addition to an entrepreneurial mindset that will support them throughout their career choices.

Read More

Ignite Founders’ Challenge - backing the next generation of early-stage entrepreneurs

26 August 2021

Judge Business School are delighted to announce Ignite Founder's Challenge starting in the Autumn term - is now open for applications. A specially designed four-week online programme for early-stage startups that consists of workshops and coaching sessions to transform your idea into a reality.

Read More

New technologies and early-stage ideas are needed for EnterpriseTECH student projects

26 August 2021

Judge Business School have an exciting opportunity for inventors. Would you like to find out if your early-stage research results or new or novel technology has commercial potential? Applications are open to submit project proposals for student teams to work on. The deadline for submissions is 6th September 2021.

Read More

Mission Therapeutics earns $20m milestone payment from AbbVie in Alzheimer’s and Parkinson’s collaboration

12 August 2021

Mission Therapeutics will receive a $20million milestone payment from AbbVie after two targets progressed to the next stage of drug discovery in their neurodegenerative disease collaboration.

Read More

Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X

06 August 2021

Artios Pharma today announced the completion of a US$153 million (£110 million) Series C financing to fund further development of its promising clinical-stage pipeline.

Read More

Bicycle Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

06 August 2021

Bicycle Therapeutics today reported financial results for the second quarter ended June 30, 2021 and provided recent corporate updates.

Read More

Stemnovate raises more than £1m to expand commercialisation of its drug discovery and diagnostic technology

06 August 2021

Stemnovate has raised more than £1million to bolster the commercialisation of its drug discovery and diagnostic technologies.

Read More

DefiniGEN Achieves ISO 9001: (2015) Certification

04 August 2021

DefiniGEN, a provider of iPSC-derived products and disease modelling services, today announces that the company has earned ISO 9001: 2015 certification at its Cambridge UK facility.

Read More

Taylor Vinters - Heading Back to Work

30 July 2021

Taylor Vinters have recently launched some free Heading Back to Work content aimed at supporting the organisations that are driving the innovation economy. Looking at Hybrid working, HR Data, and Covid vaccinations.

Read More

PetMedix monoclonal antibodies outperform benchmarks in canine study

27 July 2021

Successful performance of first-ever fully canine antibodies in dog trial paves the way for next-generation technology to meet therapeutic needs in fast­growing pet health market.

Read More

Enabling Interaction

15 July 2021

Our CEO, Derek Jones speaks to UKSPA’s BreakThrough magazine about the history, evolution and achievements of the life sciences’ community at the Babraham Research Campus.

Read More

Over £200m invested in Babraham Campus companies in last year – but what lies ahead?

15 July 2021

The Babraham Investor Conference 2021 (BIC), an event for investors focusing on early-stage and scale-up life science and med-tech companies, moved online for the first time in its 15-year history.

Read More

Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis

14 July 2021

Bicycle Therapeutics today announced that Ionis Pharmaceuticals has exercised its option and entered into an exclusive worldwide license and collaboration agreement.

Read More

F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors

14 July 2021

F-star Therapeutics today announced that it has entered into an exclusive licensing agreement with AstraZeneca.

Read More

Adrestia Therapeutics in overdrive as it hires from new Cambridge HQ

14 July 2021

Cambridge life science business Adrestia Therapeutics is scaling fast as it accelerates its mission to rebalance disease and restore health.

Read More

New breast cancer drug could be ready within five years

14 July 2021

The treatment has been created by scientists at Cancer Research UK and Artios, a spin-out it set up in Cambridge to develop the drug which has received £90 million of funding.

Read More

Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.

14 July 2021

BenevolentAI announces the appointment of Dr François Nader as Chairman.

Read More

Welcoming Dr Ian McGough to the Signalling research programme

07 July 2021

The Institute is delighted to welcome Dr Ian McGough as the newest group leader in the Signalling research programme.

Read More

Cycling Plus: Investing in Cambridge's Active Travel Network

06 July 2021

The Greater Cambridge Partnership (GCP) has launched a consultation on active travel and possible corridors for investment and would like to hear from you.

Read More

Professor Wolf Reik steps down as Institute Director

05 July 2021

The Board of Trustees has accepted the resignation of Professor Wolf Reik, FRS, FMedSci, from his position as Director of the Babraham Institute.

Read More

BI offering free FlowJo courses to the Campus in July

01 July 2021

The Babraham Flow Cytometry Facility will be giving some free virtual FlowJo courses at the end of July to FlowJo site license holders and all Babraham Campus staff.  They will be offering an options for beginners and advanced users.

Read More

Kymab Release A New Video on Life at Kymab

24 June 2021

Kymab have released a new video on their website, showing us what life at Kymab is like. Looking at careers and also featuring Babraham Research Campus.

Read More

L'Oreal Research and Innovation looking to explore technology start-ups this September & October

18 June 2021

The Open Innovation Department of L’Oréal Research and Innovation is working with the Cambridge Network to plan a virtual event during which they hope to explore innovative deep tech start-ups, and incubators and accelerators. For more information and to get involved please read more...

Read More

Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Polθ Polymerase Inhibitor in Nature Communications

18 June 2021

Artios Pharma today announced the publication of a peer reviewed article titled, “Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance” in Nature Communications.

Read More

PetMedix announces completion of the Ky9™ canine antibody discovery platform

17 June 2021

Scientists working in the labs of PetMedix Ltd have recently achieved the successful transfer of more than 4 Mbp of canine antibody DNA into the mouse genome.

Read More

Transine Therapeutics’ £9.1m will drive forward RNA therapeutics

14 June 2021

Despite progress in understanding the functions of novel long non-coding RNAs, their applications as therapeutic tools have been very limited – but that’s about to change thanks to a £9.1million seed round for Transine Therapeutics.

Read More

Transine Therapeutics Closes Extended Seed Funding of £9.1 million

02 June 2021

Transine Therapeutics announces that it successfully secured £9.1 million in seed funding. The financing was co-led by Takeda Ventures, Inc. and the Dementia Discovery Fund (DDF).

Read More

Inivata Announces Collaboration with F-star Therapeutics for the use of RaDaR™ Assay

27 May 2021

Inivata today announced a collaboration with F-star Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, for the use of Inivata’s RaDaR technology.

Read More

Babraham Institute: a new algorithm streamlines and improves flow cytometry analysis

17 May 2021

The new algorithm provides a fast and effective way to reduce errors in flow cytometry data analysis, overcoming a major restriction on harnessing the full potential of the power of flow cytometry in cell analysis.

Read More

Kalium Health appoints Kenneth Galbraith as Chair of the Board

13 May 2021

Kalium Health Ltd, which is working to help millions of people living with kidney disease and related conditions to manage their health at home, is pleased to announce the appointment of Kenneth Galbraith as Chair of the Board.

Read More

Professor Adrian Liston, Babraham Institute, and Dr Jane Osbourn OBE, Alchemab, elected to prestigious Academy of Medical Sciences Fellowship

12 May 2021

Today the Academy of Medical Sciences have announced 50 outstanding biomedical and health scientists to their Fellowship.

Read More

The Babraham Research Campus sets out its vision and ambition for its future

12 May 2021

The Babraham Research Campus’ vision is to be one of the best places in the world for discovery bioscience research and innovation; a leading sustainable ecosystem to start, nurture, scale and grow bioscience business.

Read More

Applications invited for Accelerate@Babraham life science start-up competition

10 May 2021

Accelerate@Babraham, the bio-entrepreneurial incubator initiative founded and developed by the Babraham Research Campus - supported by key industry and investor organisations - opens applications for its 2021/22 cohort today.

Read More

The Babraham Church Fund

21 April 2021

An opportunity to donate to the village Church

Read More

Alchemab raises £60 million in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics

16 April 2021

Alchemab Therapeutics today announces the completion of a £60 million ($82 million) Series A financing round.

Read More

CamBioScience & Merck: Modern PCR & NGS Methods of Clinical Relevance

08 April 2021

CamBioScience has partnered with Merck Life Sciences to provide an exciting, free online course on Modern PCR & NGS Methods of Clinical Relevance.

Read More

Artios clinches minimum $1.5bn from Novartis for cancer assault

07 April 2021

Artios Pharma, based on the Babraham Research Campus in Cambridge, has clinched a megabucks deal with Novartis that is worth at least $1.5 billion and promises fresh assaults on cancers.

Read More

The 25 Best Biotech Incubators Hatching Startup Stars in Europe

06 April 2021

Incubators can give biotech startups the boost they need to get off the ground. Accelerate@Babraham has made Labiotech's top 25 biotech incubators across Europe supporting the next generation of life science startups.

Read More

UKRI publishes their AI Review: Transforming our world with AI

06 April 2021

The AI review ’Transforming our world with AI’ sets out UKRI’s view of the opportunities for research and innovation in AI – artificial intelligence – in the UK.

Read More

Closed Loop Medicine completes recruitment into clinical study that is required for regulatory submission of its insomnia product CLM-IN01

01 April 2021

Closed Loop Medicine announces that it has completed recruitment for its critical clinical trial in the development of its combination product CLM-IN01 for insomnia.

Read More

F-star Therapeutics Reports Full-Year 2020 Financial Results and Provides Corporate Update

01 April 2021

F-star Therapeutics today announces 2020 full-year financial results and provides corporate update.

Read More

Professor Wolf Reik, FRS, FMedSci Appointed Director of the Babraham Institute

26 March 2021

The Board of Trustee Directors is delighted to announce that, following an open and international search, Professor Wolf Reik has been appointed as the Institute’s Director. Professor Reik has held the position of Acting Director since May 2020 following the tragic death of Professor Michael Wakelam.

Read More

Mission Therapeutics Welcomes Co-founder of Rosetta Capital, Jonathan Hepple, to its Board of Directors

25 March 2021

Mission Therapeutics today announces the appointment of Jonathan Hepple to the Company’s Board as a Non-Executive Director.

Read More

Meet your Neighbour: Petmedix

25 March 2021

Petmedix, based in the new Glenn Berge Building, tell us what being located on Campus means to them.

Read More

Kalium Health announces funding from National Institute for Health Research

23 March 2021

Kalium Health today announces it has been awarded funding by the National Institute for Health Research (NIHR).

Read More

PhoreMost closes £33M ($46M) Series B financing

23 March 2021

PhoreMost today announced it has completed an oversubscribed £33m ($46m) Series B investment round.

Read More

Axol and CENSO unveil merger and $5.3m investment

18 March 2021

Cell technology specialists Axol Bioscience and CENSO Biotechnologies have agreed to merge and announced an associated investment round of more than $5.3 million led by Calculus Capital and Par Equity.

Read More

Welsh startup Antiverse raises $2m for antibody discovery toolkit

16 March 2021

New biotech Antiverse has raised seed funding of £1.4 million ($2 million) to develop its artificial intelligence-based platform for discovering therapeutic antibodies.

Read More

Babraham Research Campus announces new Board Chair Appointment

15 March 2021

Babraham Bioscience Technologies Ltd (BBT), the organisation which oversees the development and day-to-day management of the Babraham Research Campus is delighted to confirm Jo Parfrey as the new BBT Board Chair.

Read More

Struggling with lab supplies?

04 March 2021

If you are facing potential disruption due to shortage of lab supplies, read on to find out how the Government are mitigating the Brexit/Covid and high demands placed on the supply chain.

Read More

Women in Science

18 February 2021

#WomenInScience day was celebrated on social media, showcasing some of the inspirational Women in Science we have on Campus.

Read More

Centessa Pharmaceuticals Launches with $250 Million Series A Financing and Unveils a New Kind of Pharmaceutical R&D Model

17 February 2021

Founded by Medicxi, Centessa Pharmaceuticals launched today as a novel asset-centric pharmaceutical company designed and built to advance a portfolio of highly validated programs.

Read More

Leading clinical immunotherapies developer Ramy Ibrahim joins bit.bio as Chief Medical Officer

17 February 2021

Biotech firm bit.bio today announces the appointment of Dr Ramy Ibrahim, MD, as Chief Medical Officer. The addition of a Chief Medical Officer is in line with the company’s plans and commitment to transition into a clinical company.

Read More

BenevolentAI Announces First Patient Dosed In Its Atopic Dermatitis Clinical Trial

17 February 2021

BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat Atopic Dermatitis.

Read More

Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients

12 February 2021

Artios Pharma today announced the start of a clinical trial of its small-molecule ATR inhibitor, ART0380, in patients with advanced or metastatic solid tumors.

Read More

Inivata takes Series C to $60m with fresh $35m raise

09 February 2021

Cambridge liquid biopsy business Inivata has raised $35 million in a second close of a Series C financing round. 

Read More

PredictImmune establishes IBD Clinical Advisory Board to advise on European access to PredictSURE IBD™

02 February 2021

PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is pleased to confirm the convening of its IBD Clinical Advisory Board (IBD CAB).

Read More

First Patients Tested with InVisionFirst®-Lung in EORTC Sponsored Phase II NSCLC Study

27 January 2021

Inivata’s InVisionFirst®-Lung is being used for ctDNA testing and monitoring of patients treated with lorlatinib Study supported by a grant from Pfizer Inc.

Read More

F-star Granted Composition of Matter Patent for FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1

27 January 2021

F-star Therapeutics today announces the European Patent Office (EPO) has granted a patent with claims protecting the composition of matter of F-star’s FS118 molecule throughout Europe.

Read More

The critical role of crossover investors

27 January 2021

The landmark sale of Kymab to Sanofi for £1.45 billion set thoughts racing among life science entrepreneurs around the world and, particularly, in the Cambridge Cluster.

Read More

Artios Pharma Expands US Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer

12 January 2021

Artios Pharma, a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, announces the appointment of Abid Ansari as Chief Financial Officer (CFO).

Read More

PetMedix partners with Boehringer Ingelheim

12 January 2021

PetMedix is pleased to announce a multi-year partnership with Boehringer Ingelheim to develop novel and transformative companion animal antibody therapeutics using PetMedix's proprietary Ky9™ platform.

Read More

Sanofi to acquire Kymab

11 January 2021

Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L.

Read More

Supporting the Eastern COVID-19 vaccination programme

08 January 2021

The NHS are seeking organisations and individuals who can give their time to support the COVID-19 vaccination programme across the East of England

Read More

Top 15 Cambridge Biotech Companies

04 January 2021

Cambridge has a large biotech scene that is starting to rival that of its US namesake. Here are the top 15 biotech companies in Cambridge you should know about.

Read More

Babraham Bioscience Technologies, which develops and manages the Babraham Research Campus, welcomes three new board members

04 January 2021

Babraham Bioscience Technologies Ltd (BBT), the organisation which oversees the development and day-to-day management of the Babraham Research Campus is pleased to welcome three new members to its board.

Read More

GSK and Ahren Announce Co-Led Series A Investment in Adrestia

10 December 2020

GSK and Ahren Announce Co-Led Series A Investment in Adrestia, and Multi-Project Discovery Collaboration with Each of the Five Projects Eligible To Receive Up To $230M (£172M) in Post Option Milestones.

Read More

F-star Therapeutics Announces First Patient Dosed in First-in-Class FS120 Phase 1 Clinical Trial

10 December 2020

FS120 is a first-in-class dual agonist tetravalent bispecific antibody that has the potential to transform outcomes for patients with difficult to treat cancers.

Read More

Merck KGaA and Artios Pharma Announce a Global Strategic Collaboration

10 December 2020

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology.

Read More

Merck KGaA and Artios Pharma Announce a Global Strategic Collaboration

10 December 2020

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology.

Read More

CELLINK and Atelerix team up to enable the shipping at room temperature of fragile 3D bioprinted constructs by the world’s bioprinting community

10 December 2020

CELLINK and Atelerix announced today a partnership to bring to market Atelerix’s portfolio of innova­tive hydrogel biological encapsulation products, which preserve fragile biological samples for shipping at room temperature.

Read More

Artios Pharma strikes stunning precision cancer drug deal worth up to $6.9bn with Merck KGaA

07 December 2020

A deal worth up to a potential $6.9billion has been struck by Artios Pharma with Merck KGaA for the development of multiple precision cancer drugs.

Read More

Paediatric HealthTech (HearGlueEar) wins Accelerate@Babraham with AstraZeneca Start-up Pitching Competition to secure £10,000 additional non-dilutive funding from CMS Ventures

26 November 2020

The Babraham Research Campus’ third cohort of Accelerate@Babraham life science start-ups went head-to-head on Wednesday afternoon (Nov 25th); competing for £10,000 additional funding generously donated by CMS Ventures.

Read More

DefiniGEN to expand in Cambridge and US after £3.25m funding round involving BGF

24 November 2020

Human cell product specialist DefiniGEN has closed a £3.25million funding round that will help it expand in Cambridge and abroad.

Read More

F-star makes NASDAQ bow as Cambridge steps up US parade

23 November 2020

F-star Therapeutics in Cambridge has wrapped up its fusion with Spring Bank Pharmaceuticals in Massachusetts and makes its NASDAQ bow tomorrow.

Read More

Start Codon closes new £15 million venture fund to translate life science innovation into successful companies

17 November 2020

Start Codon, a life science and healthcare business accelerator based in Cambridge, UK, today announced that it has closed Start Codon Fund I LP at £15 million ($20 million USD).

Read More

Genomics pioneer takes top technology role at Inivata

17 November 2020

Inivata, a Cambridge UK leader in liquid biopsy, has hired a genomics thought leader as chief technology officer. Dr Alan Schafer will spearhead the development of Inivata’s leading InVision® liquid biopsy technology platform and new product development.

Read More

Evotec and STORM Therapeutics leverage INDiGO platform to progress oncology project towards clinical studies

17 November 2020

Evotec SE announced today that, as part of its ongoing collaboration with STORM Therapeutics, STORM has selected STC-15 as a first-in-class development candidate.

Read More

PhoreMost and Oxford Biomedica enter gene therapy discovery collaboration

11 November 2020

PhoreMost Limited and Oxford Biomedica today announced that they have entered into a discovery collaboration to develop next generation CAR-T cell therapies.

Read More

Mission Therapeutics Appoints Dr Suhail Nurbhai as Chief Medical Officer

03 November 2020

Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has appointed Dr Suhail Nurbhai as Chief Medical Officer (CMO) with immediate effect.

Read More

Cambridge-Sydney alliance advances promising cancer immunotherapy

02 November 2020

Biosceptre in Cambridge UK has teamed up with Australian cancer tech trailblazer Carina Biotech to advance a promising oncology immunotherapy.

Read More

Inivata Appoints Peter Collins as Chief Business Officer

24 September 2020

Inivata, a leader in liquid biopsy, today announces the appointment of Peter Collins as Chief Business Officer, effective immediately. Peter will be responsible for leading all business development, partnering and commercial activities.

Read More

The Diversity Analysis Tool: Towards Better Diversity In Data For Precision Medicine

24 September 2020

Benevolent has launched a free open source programme to allow researchers to measure the diversity of their data.

Read More

Perfect STORM as partners explore role of RNA epigenetics in epilepsy

21 September 2020

STORM Therapeutics in Cambridge and Dublin based FutureNeuro have joined forces to explore new treatment options for people with epilepsy.

Read More

Accelerate@Babraham Start-up Programme underway with four new life science start-ups taking part in the five month programme

21 September 2020

The Babraham Research Campus’ third cohort of Accelerate@Babraham life science start-ups came together today for the first day of the 2020/21 programme.

Read More

Bicycle Therapeutics Announces First Patient Dosed in Phase IIa Trial of Bicycle® Toxin Conjugate BT1718

10 September 2020

Bicycle Therapeutics today announced that the first patient has been dosed in the Phase IIa expansion portion of the Phase I/IIa trial sponsored by Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research.

Read More

Atelerix awarded Innovate UK funding

09 September 2020

Atelerix has received a significant award under the UK Innovation and Science Seed Fund (UKI2S) Accelerator Programme from Innovate UK, the UK’s innovation agency. Funding will be used to explore scalable methods of human cell preservation, transport, and re-presentation for clinical applications.

Read More

PhoreMost and XtalPi sign AI-based pharmaceutical drug discovery collaboration agreement

09 September 2020

PhoreMost and XtalPi Inc today announced they have entered into a drug discovery collaboration agreement.

Read More

FutureNeuro partners with STORM Therapeutics to explore the role of RNA epigenetics in epilepsy

09 September 2020

We are delighted to announce that we have entered into partnership with STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, to explore new treatment options for people with epilepsy.

Read More

Ablatus wins £1.4m for technology to blitz tumours

07 September 2020

Addenbrooke’s Hospital in Cambridge will host the first clinical study into a novel technology designed to remove tumours without major surgery.

Read More

Atelerix Consortium Awarded £267,000 Innovate UK Grant

01 September 2020

Atelerix today announces that it has been awarded a grant of £267,000 from Innovate UK, the UK’s innovation agency, with collaborators Rexgenero and the Cell and Gene Therapy Catapult.

Read More

First subject dosed with ZF874, a potential disease-modifying treatment for alpha-1-antitrypsin deficiency

01 September 2020

Z Factor Ltd announced that the first human volunteer was dosed today with ZF874, its novel treatment for alpha-1-antitrypsin deficiency (AATD). AATD is a common genetic disorder, affecting around in 1 in 2000 people in Western countries.

Read More

Cambridge entrepreneur and investor has been announced as a winner in the regional stage of the Barclays’ Entrepreneur Awards

01 September 2020

Barclays’ Entrepreneur Awards highlight and recognise entrepreneurs who are transforming their industries, the economy and society. Dr Andy Richards, CBE, has received the accolade in the Icon category which seeks to recognise entrepreneurs who have successfully turned their vision into reality.

Read More

Bicycle Therapeutics Announces First Patient Dosed in Oxurion’s Phase II Trial Using a Novel Bicycle®-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema

01 September 2020

Bicycle Therapeutics today announced that the first patient has been dosed in Oxurion’s Phase II study of THR-149, a novel Bicycle-based plasma kallikrein (PKal) inhibitor, in patients with diabetic macular edema (DME).

Read More

Reflection Therapeutics secures co-funding from Innovate UK for major research programme to fight motor neurone disease through cell therapy

13 August 2020

Reflection Therapeutics, Cambridge-based developer of cell therapy against neuroinflammation, is pleased to announce the start of a major Innovate Smart Grant project co-funded by Innovate UK, the UK’s innovation agency.

Read More

Bicycle Therapeutics Appoints Dr. Dominic Smethurst as Chief Medical Officer

11 August 2020

Bicycle Therapeutics, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of Dominic Smethurst, MA, MBChB, MRCP, MFPM as Chief Medical Officer.

Read More

Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine to Pursue Mission of Creating Next Generation Immunotherapies

05 August 2020

Spring Bank Pharmaceuticals and F-star Therapeutics today announced that the companies have entered into a definitive share exchange agreement.

Read More

Bicycle Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

05 August 2020

Bicycle Therapeutics today reported financial results for the second quarter ended June 30, 2020 and discussed recent corporate updates.

Read More

Decoding cell programming

05 August 2020

Bit Bio has partnered with the London Institute for Mathematical Sciences on a moonshot mission to create every human cell type for use in biomedical research.

Read More

Closed Loop Medicine secures £250,000 Innovate UK continuity funding

30 July 2020

Closed Loop Medicine has secured £250,000 from Innovate UK to support clinical evaluation of a drug + digital combination product for hypertension and COVID- 19 monitoring.

Read More

Abzena Receives Growth Capital Investment from Newly Launched Biospring Partners

30 July 2020

Abzena has announced a $10M investment of growth capital from Biospring Partners, a New York based investment firm.

Read More

Sphere Fluidics and Heriot-Watt University collaborate to develop next generation droplet generator instrumentation

24 July 2020

Sphere Fluidics today announced they have been awarded a Knowledge Transfer Partnership (KTP) grant from Innovate UK, the UK’s innovation agency.

Read More

Merck KGaA, Darmstadt, Germany Takes an Early Option in Immuno-Oncology Collaboration

24 July 2020

F-star Therapeutics Ltd today announces further progress in its long-standing immuno-oncology collaboration with Merck KGaA, Darmstadt, Germany.

Read More

Stemnovate creates rapid detection kit for Covid-19

21 July 2020

The Babraham Research Campus-based molecular biology and microengineering company says the kit overcomes the drawbacks with current PCR-based testing and offers an economical solution suitable for deployment at businesses, care homes, airports and other key locations.

Read More

Closed Loop Medicine boosts team with key appointment of Melissa Strange as Chief Financial Officer

16 July 2020

Closed Loop Medicine, the London-based therapeutics and health tech company strengthens its leadership team with several new appointments including a top finance director.

Read More

Bit Bio deal gives BioMed Realty full house at Babraham flagship

16 July 2020

US property powerhouse BioMed Realty has completed the lease-up of its landmark scheme at the Babraham Research Campus in Cambridge UK, underlining the strength of the life science cluster.

Read More

Clinical Data Validates BenevolentAI's AI Predicted Hypothesis For Baricitinib As A Potential Treatment For COVID-19

08 July 2020

BenevolentAI today announced the publication of further experimental data in support of its AI-derived hypothesis for baricitinib as a potential treatment for COVID-19 in the Journal: EMBO Molecular Medicine.

Read More

Mission and Imperial College London Report Potent and Selective Probe for Deubiquitylating Enzyme UCHL1

08 July 2020

Working in close collaboration, scientists from the Tate Group, Imperial College London, and drug discovery and development company, Mission Therapeutics, have discovered the first exquisitely selective probe for a deubiquitylating enzyme (DUB).

Read More

Mission Raises $15m and Expands its Relationship with Pfizer

07 July 2020

Mission Therapeutics today announced that it has raised $15m (£12m) in equity investment. The round was led by existing investor Pfizer Ventures, the venture capital arm of Pfizer Inc.

Read More

The Babraham Research Campus: At the forefront in supporting the UK’s bioscience enterprises and the evidence which proves it!

06 July 2020

A new report published in June this year, confirms the Babraham Research Campus as one of the leading lights in the UK when it comes to delivering a supportive ecosystem to enable the commercialisation of life science research.

Read More

New report confirms the Babraham Research Campus at the forefront in supporting the UK’s early-stage bioscience enterprises

16 June 2020

Research led by an academic team from the University of Cambridge has demonstrated the benefits and outputs from the significant taxpayer investment into the Babraham Research Campus; evidencing the overall economic, social and scientific contribution the Campus makes to the UK economy.

Read More